Search research articles
Contact Us
Filters
Showing results (121-130 of 357) with videos related to
Page
of 36
Sort By:
The Lancet. Oncology
|
June 12, 2010
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
Guru Sonpavde, Cora N Sternberg, Jonathan E Rosenberg, et al.
Oncology
|
February 23, 2016
Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma
Jose Diaz, Cora N Sternberg, Faisal Mehmud, et al.
Critical Reviews in Oncology/Hematology
|
February 14, 2002
Bladder cancer
Filippo de Braud, Massimo Maffezzini, Vito Vitale, et al.
European Urology
|
June 21, 2011
Sequelae of treatment in long-term survivors of testis cancer
Robert Abouassaly, Sophie D Fossa, Aleksander Giwercman, et al.
European Urology
|
May 28, 2013
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer
Benjamin A Gartrell, Robert E Coleman, Karim Fizazi, et al.
European Urology
|
August 30, 2011
Contemporary role of androgen deprivation therapy for prostate cancer
Vincenzo Pagliarulo, Sergio Bracarda, Mario A Eisenberger, et al.
The Journal of Urology
|
November 22, 2017
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies
Marco Moschini, Shahrokh F Shariat, Morgan Rouprêt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 17, 2018
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
Ana M Molina, Thomas E Hutson, Dmitry Nosov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma
Guru Sonpavde, Jonathan E Rosenberg, Noah M Hahn, et al.
The Lancet. Oncology
|
February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Bertrand Tombal, Fred Saad, David Penson, et al.
Page
of 36
Search research articles
Search
Showing results (121-130 of 357) with videos related to
Sort By:
Page
of 36
The Lancet. Oncology
|
June 12, 2010
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
Guru Sonpavde, Cora N Sternberg, Jonathan E Rosenberg, et al.
Oncology
|
February 23, 2016
Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma
Jose Diaz, Cora N Sternberg, Faisal Mehmud, et al.
Critical Reviews in Oncology/Hematology
|
February 14, 2002
Bladder cancer
Filippo de Braud, Massimo Maffezzini, Vito Vitale, et al.
European Urology
|
June 21, 2011
Sequelae of treatment in long-term survivors of testis cancer
Robert Abouassaly, Sophie D Fossa, Aleksander Giwercman, et al.
European Urology
|
May 28, 2013
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer
Benjamin A Gartrell, Robert E Coleman, Karim Fizazi, et al.
European Urology
|
August 30, 2011
Contemporary role of androgen deprivation therapy for prostate cancer
Vincenzo Pagliarulo, Sergio Bracarda, Mario A Eisenberger, et al.
The Journal of Urology
|
November 22, 2017
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies
Marco Moschini, Shahrokh F Shariat, Morgan Rouprêt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 17, 2018
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
Ana M Molina, Thomas E Hutson, Dmitry Nosov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma
Guru Sonpavde, Jonathan E Rosenberg, Noah M Hahn, et al.
The Lancet. Oncology
|
February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Bertrand Tombal, Fred Saad, David Penson, et al.
Page
of 36